-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Decreased cognitive ability can lead to dementia, and it will be accompanied by the accumulation of beta amyloid (Aβ) in nerve plaques and the appearance of neurofibrillary tangles (NFT) composed of highly phosphorylated tau protein (tau).
Measure the concentration of axitinib in mouse plasma and brain tissue
Image source: Chaahat SB Singh, et al.
The researchers said that the drug called Axitinib can inhibit the growth of new blood vessels in the brain.
Previously, potential Alzheimer's disease treatments have shown certain promise in animal models, but they have repeatedly failed in clinical trials
The early research results of Professor Jefferies laid the foundation for the results of this article.
After using axitinib for only one month, the researchers were able to greatly reduce the formation of blood vessels in the mice, and restore the function of the blood-brain barrier.
Nevertheless, researchers are still very optimistic that if the drug axitinib performs well in the human body, researchers may redirect it for the treatment of Alzheimer's disease
In summary, the results of this article show that the use of the anticancer drug axitinib to target the pro-angiogenic pathways in patients with Alzheimer's disease may significantly reduce the formation of new blood vessels in the brain and restore blood.
Note: The original text has been deleted
Original source:
Chaahat SB Singh, Kyung Bok Choi, Lonna Munro, et al.
